COX-2, TFF1, and Src define better prognosis in young patients with gastric cancer

Authors

Errata

This article is corrected by:

  1. Errata: Erratum Volume 109, Issue 2, 175, Article first published online: 5 November 2013

  • All authors declare that they have no conflicts of interest for the manuscript presented here.

Abstract

Background and Objectives

Despite its dwindling occurrence, gastric cancer remains a leading cause of cancer related mortality worldwide. Molecular determinants of prognosis that impact survival are being sought out as a means to facilitate rational clinical decision-making and enhance patient management. In this study, we evaluated three molecules implicated in gastric carcinogenesis and demonstrated that the differential expression of cyclooxygenase-2 (COX-2) and the viral oncogene homolog Src proteins could explain the differences in survival observed in patients older and younger than 50 years of age.

Methods

We evaluated 5-year survival in a cohort of 423 gastric cancer patients using chronological age as a variable. Additionally, we assessed the protein expression of three molecules (COX-2, TFF1, Src) implicated in the pathogenesis of gastric cancer using immunohistochemistry.

Results

We found that patients younger than 50 years of age had a better 5-year survival rate in all tumor stages. We found that the expression of COX-2 and Src correlated significantly with survival in this group without any significant impact attributable to TFF1.

Conclusions

Our study demonstrates that young gastric cancer patients have a better prognostic outlook that could in part be explained by the differential expression of COX-2 and Src. J. Surg. Oncol. 2013; 108:409–413. © 2013 Wiley Periodicals, Inc.

Ancillary